info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Nintedanib (Ofev)
503
Article source: Seagull Pharmacy
Sep 12, 2025

Nintedanib (Ofev) was approved for marketing by the U.S. FDA in 2014. It is a tyrosine kinase inhibitor developed by Boehringer Ingelheim, indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Indications for Nintedanib (Ofev)

Primary Indications

Nintedanib (Ofev) is explicitly indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Idiopathic pulmonary fibrosis is a chronic, progressive, fibrotic interstitial lung disease characterized by fibrosis of the lung parenchyma and abnormal remodeling of alveolar structures, leading to progressive deterioration of lung function.

Dosage Forms, Strengths and Composition of Nintedanib (Ofev)

Strengths and Dosage Forms

Nintedanib is available as soft capsules in two strengths.

150mg capsules: Brown opaque oval soft capsules, imprinted in black with Boehringer Ingelheim's logo and the text "150".

100mg capsules: Peach opaque oval soft capsules, imprinted in black with Boehringer Ingelheim's logo and the text "100".

Composition

Active Ingredient

Each capsule contains 150mg or 100mg of nintedanib (present as the ethanesulfonate salt, corresponding to 180.60mg and 120.40mg of nintedanib ethanesulfonate, respectively).

Excipients

Filling materials: Triglycerides, stearin, lecithin.

Capsule shell: Gelatin, glycerin, titanium dioxide, iron oxide red, iron oxide yellow.

Printing ink: Shellac, iron oxide pigments.

Chemical Properties

Nintedanib ethanesulfonate is a bright yellow powder. Its chemical name is a 1H-indole-6-carboxylic acid derivative, with a molecular formula of C₃₁H₃₃N₅O₄·C₂H₆O₃S and a molecular weight of 649.76 g/mol.

The solubility of this compound increases at pH < 3; however, clinical studies have shown that proton pump inhibitors or H₂ receptor antagonists do not affect its exposure.

Dosage and Administration of Nintedanib (Ofev)

Standard Dosing Regimen

Recommended dose: 150mg twice daily (approximately 12 hours apart), taken with food.

The maximum daily dose should not exceed 300mg.

Administration Requirements

Capsules must be swallowed whole; chewing or crushing is not allowed.

If a dose is missed, do not make up for it; take the next dose at the originally scheduled time.

Liver function tests are required before initiating treatment.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
What Are the Side Effects of Pirfenidone (Esbriet)?
Pirfenidone (Esbriet) is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF). It slows down disease progression by regulating the fibrotic process. Its use may be accompanied by...
How Effective is Pirfenidone (Esbriet) in Treatment?
Pirfenidone (Esbriet) is an oral antifibrotic medication used for the treatment of idiopathic pulmonary fibrosis (IPF). It slows down disease progression by inhibiting the fibrotic process.How Effecti...
Precautions for the Use of Pirfenidone (Esbriet)
Pirfenidone (Esbriet) is a pyridone drug used for the treatment of idiopathic pulmonary fibrosis (IPF). It slows down disease progression by inhibiting the fibrosis process. Its efficacy has been veri...
How to Use Pirfenidone (Esbriet)
Pirfenidone (Esbriet) is a pyridone-based medication used for the treatment of idiopathic pulmonary fibrosis (IPF). Its use must strictly follow the dose titration protocol, and the dosage should be a...
How to Use Nintedanib (Ofev)
Nintedanib (Ofev) is a kinase inhibitor primarily indicated for the treatment of patients with idiopathic pulmonary fibrosis (IPF).How to Use Nintedanib (Ofev)Recommended DosageThe standard recommende...
Precautions for Nintedanib (Ofev) Administration
Nintedanib (Ofev) is a tyrosine kinase inhibitor used for the treatment of idiopathic pulmonary fibrosis (IPF). It exerts its effects by inhibiting targets such as platelet-derived growth factor recep...
How Effective is Nintedanib (Ofev) in Treatment?
As a targeted drug for the treatment of idiopathic pulmonary fibrosis (IPF), nintedanib (Ofev) slows disease progression by inhibiting a variety of tyrosine kinases.How Effective is Nintedanib (Ofev) ...
What Are the Side Effects of Nintedanib (Ofev)?
Nintedanib (Ofev) is a targeted drug used for the treatment of idiopathic pulmonary fibrosis (IPF). It slows down disease progression by inhibiting a variety of tyrosine kinases. Its clinical use may ...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved